NCT06794775View on ClinicalTrials.gov

SWE-NEO: Swedish NeoAdjuvant Trial Comparing Monotherapy to Combined Immunotherapy in Resectable Stage III Melanoma

PHASE3RecruitingINTERVENTIONAL
Enrollment

128

Participants

Timeline

Start Date

July 10, 2025

Primary Completion Date

April 15, 2032

Study Completion Date

April 15, 2032

Conditions
Malignant Melanoma Stage III
Interventions
DRUG

Nivolumab

Adjuvant monotherapy with Nivolumab

DRUG

Nivolumab + Ipilimumab

Adjuvant combination therapy with Nivolumab and Ipilimumab

Trial Locations (3)

Unknown

NOT_YET_RECRUITING

Sahlgrenska University Hospital, Gothenburg

NOT_YET_RECRUITING

Skane University Hospital, Lund

RECRUITING

Karolinska University Hospital, Stockholm

All Listed Sponsors
lead

Hildur Helgadottir

OTHER